Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 3;6(10):a026831.
doi: 10.1101/cshperspect.a026831.

HDACs and HDAC Inhibitors in Cancer Development and Therapy

Yixuan Li  1 , Edward Seto  1
Affiliations
Review

HDACs and HDAC Inhibitors in Cancer Development and Therapy

Yixuan Li et al. Cold Spring Harb Perspect Med. .

Abstract

Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture. Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes. In addition, HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biological processes including cancer initiation and progression. This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A simplistic illustration of the diverse functions of HDACs and HDACi regulating different stages of cancer through multiple different mechanisms and changing different biological processes. Far right, ↑ indicates promotion or up-regulation, ↓ indicates repression or down-regulation.
See this image and copyright information in PMC

References

    1. Adams H, Fritzsche FR, Dirnhofer S, Kristiansen G, Tzankov A. 2010. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin Ther Targets 14: 577–584. - PubMed
    1. Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, Friess H, Buchler M, Evert M, Lerch MM, et al. 2012. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61: 439–448. - PubMed
    1. Ahn MY, Ahn JW, Kim HS, Lee J, Yoon JH. 2015. Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells. Oncol Rep 33: 1899–1907. - PubMed
    1. Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, et al. 2015. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics 10: 431–445. - PMC - PubMed
    1. Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Hsieh YT, Kim YM, Lomenick B, Okemoto K, Landaw EM, Wang D, et al. 2011. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymphoma 52: 1544–1555. - PMC - PubMed

MeSH terms

Substances